Immunotherapy

 

The immune system is a system of cells and organs whose function is to defend an organism from foreign pathogens. With the ability to mount a response against virtually any foreign material and return to a quiescent state following neutralization of the threat, this fascinating organ system displays remarkable specificity and plasticity. To achieve this, there is a multifaceted balancing act between the many activators and suppressors that maintains homeostasis of perhaps the body’s most complex organ system.

Activation of the immune system involves a number of checkpoints in order to ensure proper activation. For instance, T cell activation requires binding of the T cell receptor to the MHC antigen, yet this interaction alone is not sufficient for producing a T cell response. Full T cell activation and inactivation requires the coordination of a multitude of co-stimulatory and inhibitory signals. For example, T cell activation can result from the combination of MHC:TCR and B7-1:CD28 interaction. In contrast, B7-1 binding to CTLA4 results in an inhibitory signal that prevents activation.

Given its diverse function and the fact that the immune system plays a role in virtually all human diseases, immunotherapy has become an important approach for the treatment of numerous diseases. Immunotherapy is defined as the treatment of disease by inducing, enhancing, or suppressing an immune response. This often involves targeting immunoreceptors, such as those discussed above, with small molecule inhibitors/activators or immune system components, including antibodies or antibody fragments (Fab). Immunotherapies have shown efficacy in the treatment of cancer, autoimmune diseases, inflammatory diseases, and more.

BPS Bioscience offers many purified, soluble immunoreceptors involved in key immunosignaling pathways. Additionally, we offer a number of assay kits that can be used to screen for inhibitors of protein-protein interaction, as well as neutralizing antibodies to serve as positive controls for inhibition.

References:

1.  Pardoll, D.M., Nat. Rev. Cancer. 2012; 12: 252-264.
2.  Lesterhuis, W.J., et al., Nat. Rev. Drug. Disc. 2011; 10: 591-600.

Immunotherapy Subcategories

Items 1 to 25 of 416 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Catalog#SizeProduct NamePrice
71290-1 50 ug Anti-PD-1 Neutralizing Antibody, PE-labeled
$325
79058 100 μg B7-1 (CD80) (Mouse), Fc fusion (Human), Avi-Tag
$300
33297 100 ml 3x CLTA4 Assay Buffer
$195
74000 10 ml 5X CD73 Assay Buffer
$185
60540 2 vials ADCC Bioassay Effector Cell F variant (Low Affinity) - Jurkat Recombinant Cell Line
$2,500
60541 2 vials ADCC Bioassay Effector Cell V variant (High Affinity) - Jurkat Recombinant Cell Line
$2,500
71273 2 vials ADCP Bioassay Effector Cell FcγRIIa (H variant) /NFAT Reporter-Jurkat
$2,500
79097-1 50 μg Anti-CD137 Agonist Antibody
$325
79097-2 100 μg Anti-CD137 Agonist Antibody
$445
71209 100 µg Anti-CD20 Agonist Antibody
$300
71274-1 50 µg Anti-CD3 Agonist Antibody
$325
71274-2 100 µg Anti-CD3 Agonist Antibody
$465
79065-1 50 µg Anti-CD47 Antagonist Antibody
$325
79065-2 100 µg Anti-CD47 Antagonist Antibody
$445
79105-2 100 μg Anti-CD47 Antibody, PE-Labeled
$485
79105-1 50 μg Anti-CD47 Antibody, PE-Labeled
$365
71212 100 µg Anti-CTLA4 Neutralizing Antibody
$445
79053-1 50 µg Anti-GITR Antibody
$325
79053-2 100 µg Anti-GITR Antibody
$445
71295-1 50 μg Anti-GITR Antibody, PE-labeled
$325
71295-2 100 μg Anti-GITR Antibody, PE-labeled
$465
91015 100 μg Anti-IL-17A Neutralizing Antibody
$445
71226-2 100 μg Anti-LAG3 Antibody, PE-Labeled
$465
71226-1 50 μg Anti-LAG3 Antibody, PE-Labeled
$325
71219 100 µg Anti-LAG3, Neutralizing Antibody
$445

Items 1 to 25 of 416 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5